ObsEva SA (OBSV): Price and Financial Metrics


ObsEva SA (OBSV): $3.15

-0.01 (-0.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OBSV to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

OBSV Stock Price Chart Interactive Chart >

Price chart for OBSV

OBSV Price/Volume Stats

Current price $3.15 52-week high $5.55
Prev. close $3.16 52-week low $1.86
Day low $3.09 Volume 565,200
Day high $3.23 Avg. volume 2,981,525
50-day MA $2.81 Dividend yield N/A
200-day MA $3.01 Market Cap 181.29M

ObsEva SA (OBSV) Company Bio


ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women between the ages of 15 and 49 suffering from reproductive health and pregnancy. The company intends to develop treatments for treating endometriosis, uterine fibroids, and preterm labor. The company was founded in 2012 and is based in Switzerland.


OBSV Latest News Stream


Event/Time News Detail
Loading, please wait...

OBSV Latest Social Stream


Loading social stream, please wait...

View Full OBSV Social Stream

Latest OBSV News From Around the Web

Below are the latest news stories about ObsEva SA that investors may wish to consider to help them evaluate OBSV as an investment opportunity.

ObsEva Submits NDA Of Linzagolix To FDA For Treatment Of Uterine Fibroids

(RTTNews) - ObsEva SA (OBSV) said Wednesday that it has submitted a New Drug Application to the U.S. Food and Drug Administration for linzagolix for the treatment of uterine fibroids. Linzagolix is an oral GnRH receptor antagonist with potential best-in-class efficacy, favorable tolerability profile, and unique and flexible dosing options.

Business Insider Markets | September 15, 2021

ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids

- If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of more women with uterine fibroids -

Intrado Digital Media | September 15, 2021

ObsEva SA: ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids

-If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of more women with uterine fibroids- -NDA submission includes positive dat

FinanzNachrichten | September 15, 2021

ObsEva (OBSV) Files NDA for Linzagolix to Treat Uterine Fibroids

ObsEva (OBSV) submits an NDA to the FDA for linzagolix as a potential treatment for uterine fibroids.

Yahoo | September 15, 2021

The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC) aTyr Pharma, Inc. (NASDAQ: LIFE) (reacted to positive analyst action following a positive clinical readout announced Monday) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) BELLUS Health Inc. (NASDAQ: BLU) Itamar Medical Ltd. (NASDAQ: ITMR) IVERIC bio, Inc. (NASDAQ: ISEE) Kezar Life Sciences, Inc. (NASDAQ: KZR) PPD, Inc. (NASDAQ: P

Yahoo | September 15, 2021

Read More 'OBSV' Stories Here

OBSV Price Returns

1-mo 10.14%
3-mo 3.28%
6-mo 3.96%
1-year 28.05%
3-year -82.57%
5-year N/A
YTD 51.44%
2020 -45.55%
2019 -69.83%
2018 29.71%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.373 seconds.